|
Age
|
1.001 (0.983–1.019)
|
0.902
| | |
|
Gender (male vs. female)
|
1.048 (0.729–1.509)
|
0.799
| | |
|
BMI
|
1.005 (0.945–1.068)
|
0.884
| | |
|
ASA score (1 vs. 2 vs. 3)
|
1.053 (0.700–1.583)
|
0.804
| | |
|
Charlson comorbidity index (0 vs. 1 vs. ≥ 2)
|
0.846 (0.646–1.109)
|
0.226
| | |
|
Year of operation (2013–2015 vs. 2016–2017)
|
0.708 (0.467–1.073)
|
0.103
| | |
|
Tumor differentiation (well-moderate vs. poor)
|
1.909 (1.318–2.764)
|
0.001
|
2.020 (1.368–2.984)
|
< 0.001
|
|
Nerve invasion (yes vs. no)
|
1.168 (0.749–1.821)
|
0.494
| | |
|
T stage (1 vs. 2 vs. 3)
|
1.459 (1.041–2.045)
|
0.028
|
1.452 (0.986–2.138)
|
0.059
|
|
N stage (0 vs. 1 vs. 2)
|
1.294 (1.009–1.659)
|
0.042
|
1.140 (0.478–2.718)
|
0.768
|
|
AJCC TNM stage (I vs. II vs. III)
|
1.334 (1.037–1.716)
|
0.025
|
1.167 (0.467–2.915)
|
0.740
|
|
Adjuvant treatment (yes vs. no)
|
0.410 (0.290–0.580)
|
< 0.001
|
0.364 (0.245–0.539)
|
< 0.001
|
|
Operative time
|
1.000 (0.999–1.002)
|
0.693
| | |
|
Estimated blood loss
|
1.000 (0.999–1.001)
|
0.712
| | |
|
Blood transfusion (yes vs. no)
|
1.107 (0.704–1.742)
|
0.659
| | |
|
No. of resected lymph nodes
|
1.012 (0.994–1.031)
|
0.191
| | |
|
R0 resection (yes vs. no)
|
0.342 (0.085–1.385)
|
0.133
| | |
|
Surgical approach (LPD vs. OPD)
|
1.483 (1.031–2.135)
|
0.034
|
1.042 (0.675–1.608)
|
0.853
|
